{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:23:11Z","timestamp":1787743391806,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To compare prophylactic oral cephalexin and metronidazole with placebo for 48 hours after cesarean delivery following membrane rupture on the frequency of composite infection morbidity postpartum among pregnant individuals with obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      This randomized, double-blind clinical trial was conducted at two medical centers from August 2017 to August 2023. We enrolled women with obesity (pregnancy body mass index [BMI] 30 or higher) and ruptured membranes (for 4 hours or more) undergoing cesarean delivery who were also receiving standard intravenous preoperative prophylaxis with cefazolin and azithromycin. Participants were assigned randomly to receive either oral cephalexin (500 mg) and metronidazole (500 mg) or an identical placebo every 8 hours for 48 hours after their cesarean delivery. The primary outcome was a\n                      <jats:italic toggle=\"yes\">composite of infection complications<\/jats:italic>\n                      , defined as a composite of endometritis, surgical site infection, or other postcesarean infections (pelvic septic thrombosis, abdominal or pelvic abscess based on radiologic diagnosis) within 30 days after cesarean delivery. With an anticipated relative risk reduction of 50% and a two-sided \u03b1=.05 with 80% power and a 1:1 ratio of exposed to unexposed, a total sample size of 302 participants was planned to detect a reduction in the primary outcome from 25% in the placebo group to 12.5% in the antibiotic group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of the 321 women who were randomized (mean\u00b1SD age 27.5\u00b16.1 years, mean\u00b1SD BMI 38.4\u00b16.8), 160 received cephalexin\u2013metronidazole and 161 received placebo with a total of 284 (88.5%) who completed the study per protocol. The overall rate of the composite infection outcome was 6.2% (95% CI, 3.8\u20139.5%). In the cephalexin\u2013metronidazole group, 9 women (5.6%) developed the composite compared with 11 women (6.8%) in the placebo group (difference 1.2%, 95% CI, \u22122.5% to 5.0%; odds ratio 0.81, 95% CI, 0.33\u20132.02;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.64). No serious adverse events, including allergic reactions, were reported in either group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In women with obesity undergoing cesarean delivery with an extended-spectrum preoperative antibiotic regimen that included azithromycin, the addition of a postoperative 48-hour course of oral cephalexin and metronidazole did not significantly lower the rate of infection complications within 30 days after delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT03187106.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005936","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T17:00:57Z","timestamp":1747933257000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Prophylactic Oral Cephalexin and Metronidazole Compared With Placebo After Cesarean Delivery to Reduce Infection Complications in Women With Obesity"],"prefix":"10.1097","volume":"146","author":[{"given":"Antonio F.","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Kuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"McDonnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Saade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/676022","article-title":"Strategies to prevent surgical site infections in acute care hospitals: 2014 update","volume":"35","author":"Anderson","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1503\/cmaj.060870","article-title":"Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term","volume":"176","author":"Liu","year":"2007","journal-title":"CMAJ"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/01.AOG.0000219750.79480.84","article-title":"Maternal morbidity associated with multiple repeat cesarean deliveries","volume":"107","author":"Silver","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.AOG.0000233154.62729.24","article-title":"Postpartum maternal mortality and cesarean delivery","volume":"108","author":"Deneux-Tharaux","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/01.AOG.0000124568.71597.ce","article-title":"Maternal morbidity associated with vaginal versus cesarean delivery","volume":"103","author":"Burrows","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"100144","DOI":"10.1016\/j.xagr.2022.100144","article-title":"Surgical site infection following cesarean delivery incidence, risk factors, and association with incremental healthcare use","volume":"3","author":"Jang","year":"2023","journal-title":"AJOG Glob Rep"},{"key":"R7-20260826","first-page":"1","article-title":"Births: final data for 2014","volume":"64","author":"Hamilton","year":"2015","journal-title":"Natl Vital Stat Rep"},{"key":"R8-20260826","first-page":"1","article-title":"Births: final data for 2018","volume":"68","author":"Martin","year":"2019","journal-title":"Natl Vital Stat Rep"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"e0148343","DOI":"10.1371\/journal.pone.0148343","article-title":"The increasing trend in caesarean section rates: global, regional and national estimates: 1990-2014","volume":"11","author":"Betr\u00e1n","year":"2016","journal-title":"PLoS One"},{"key":"R10-20260826","first-page":"367","article-title":"Risk factors for postcesarean surgical site infection","volume":"95","author":"Tran","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"suppl 8","key":"R11-20260826","first-page":"IV-26","article-title":"Assessing comorbidity using claims data: an overview","volume":"40","author":"Klabunde","year":"2002","journal-title":"Med Care"},{"key":"R12-20260826","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/655435","article-title":"Comparison of costs of surgical site infection and endometritis after cesarean delivery using claims and medical record data","volume":"31","author":"Olsen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa1602044","article-title":"Adjunctive azithromycin prophylaxis for cesarean delivery","volume":"375","author":"Tita","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20260826","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jama.2017.10567","article-title":"Effect of post-cesarean delivery oral cephalexin and metronidazole on surgical site infection among obese women: a randomized clinical trial","volume":"318","author":"Valent","year":"2017","journal-title":"JAMA"},{"key":"R15-20260826","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/AOG.0000000000002333","article-title":"Adding azithromycin to cephalosporin for cesarean delivery infection prophylaxis: a cost-effectiveness analysis","volume":"130","author":"Skeith","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/AOG.0000000000002129","article-title":"Economic evaluation of adjunctive azithromycin prophylaxis for cesarean delivery","volume":"130","author":"Harper","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/AOG.0000000000002833","article-title":"Use of prophylactic antibiotics in labor and delivery. ACOG Practice Bulletin No. 199. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R19-20260826","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/AOG.0000000000000384","article-title":"Extreme obesity and postcesarean maternal complications","volume":"124","author":"Stamilio","year":"2014","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:00:17Z","timestamp":1787742017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005936"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005936","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"2025-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}